Journal of Developing Drugs
Open Access
ISSN: 2329-6631
+44 1478 350008
ISSN: 2329-6631
+44 1478 350008
Ikechukwu V Onyishi
University of Nigeria, Nigeria
Posters & Accepted Abstracts: J Develop Drugs
Edible phytolipids from Irvingia wombolu (IW) combined with Phospholipon 90H (P90H) formed structurally modified lipids as a vehicle for the delivery of a BCS class II drug, rifampicin, offering increased pay load of drug in addition to increased physical stability. Rifampicin-loaded Solid Lipid Microparticles (SLMs) using structurally modified lipid matrices based on IW Fats (IWF) and P90H were formulated. The rifampicin-loaded SLMs were prepared using P90H and IWF at optimized concentrations of 1:2 and 1:3, respectively, and characterised in terms of particle size and morphology, pH, Encapsulation Efficiency (EE), thermal stability and stability in Simulated Gastric Fluid (SGF, pH 1.2), in vitro/in vivo release and antimicrobial susceptibility studies. The particle size ranged from 32�±7.64 to 55�±26.46 �¼m, pH was stable over 3 months and EE range of 84 to 91.6 % were obtained. Rifampicin-loaded SLMs had about 21.2% degradation at 4 h in SGF, while rifampicin pure sample had 63.9% degradation. SLMs had about 66.2 to 81.1% release in Simulated Intestinal Fluid (SIF, pH 7.4) at 12 h and also exhibited significantly higher in vivo absorption of rifampicin than the reference commercial sample (p<0.05). Rifampicin-loaded SLMs also exhibited good activities against Staphylococcus aureus, Bacillus subtilis, E. coli and Klebsiella pneumonia. The formulated rifampicin-loaded SLMs had good in vitro and in vivo properties and also exhibited sustained release properties for once daily administration. Method of SLM preparation adopted is straightforward and the produced SLMs indicated sustained drug release, better in vivo bioavailability, prevention of acidic degradation of rifampicin and good antimicrobial properties.
Email: docikeonyishi@gmail.com